<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056962</url>
  </required_header>
  <id_info>
    <org_study_id>813</org_study_id>
    <nct_id>NCT04056962</nct_id>
  </id_info>
  <brief_title>Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma</brief_title>
  <official_title>Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the efficacy and safety of topical application of
      tacrolimus for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kaposiform hemangioendothelioma (KHE) and tufted angiomas (TA) are rare vascular tumors,
      which are apparent predominantly in infancy or early childhood. Currently, no standard
      treatment regimens exist for KHE/TA. The aim of this study was to evaluate the efficacy and
      safety of topical application of tacrolimus for superficial Kaposiform hemangioendothelioma
      (KHE) and tufted angioma (TA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in the size of the lesion</measure>
    <time_frame>2.5 years</time_frame>
    <description>Therapeutic effect is evaluated by reduction in the size of the tumor measured by centimeters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse events</measure>
    <time_frame>2.5 years</time_frame>
    <description>using the measurement of ratio to evaluate the rate of adverse events of topical application of tacrolimus (such as ratio of Acne vulgaris, pruritis and rash etc.).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma</condition>
  <arm_group>
    <arm_group_label>patients treated with Tacrolimus ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus ointment</intervention_name>
    <description>topical application of tacrolimus for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).</description>
    <arm_group_label>patients treated with Tacrolimus ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma
             (TA)

        Exclusion Criteria:

          -  Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and
             tufted angioma (TA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Ji</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Ji, PHD, MD</last_name>
    <phone>+86 13980544622</phone>
    <email>jijiyuanyuan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ji, MD</last_name>
      <phone>86 18980606865</phone>
      <email>jijiyuanyuan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yi Ji</investigator_full_name>
    <investigator_title>Doctor of Philosophy, Doctor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Kasabach-Merritt Syndrome</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

